Hepatitis C can be transmitted through blood transfusions, organ transplants, percutaneous (especially IV drug use), sexual or perinatal route.
It has an incubation period of 14-180 days.
Goal of treatment is to prevent progression to chronic hepatitis C through antiviral treatment of acute hepatitis C. Also, it aims to prevent occurrence of liver-related complications through antiviral treatment of chronic hepatitis C.
A once-daily oral dose of sofosbuvir and velpatasvir for 12 weeks leads to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection, according to an Asian study. However, the efficacy of this regimen may be reduced in patients with HCV genotype 3b with cirrhosis.
Treatment with the combination of the DAAs* glecaprevir and pibrentasvir led to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection genotype 5 or 6, according to the phase IIIB ENDURANCE-5,6** trial.
Most liver tumours may be identified at early stages in cirrhotic patients treated with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, a study reports. Risk factors for increased risk of hepatocellular carcinoma following DAA therapy include male sex, diabetes and noninvasive markers of liver fibrosis.
In patients with genotype 3 hepatitis C virus (HCV) infection and decompensated cirrhosis, the rate of achieving sustained virologic response 12 weeks after treatment (SVR12) is high with treatment regimens consisting of sofosbuvir and velpatasvir with or without ribavirin, according to the results of a phase II trial. However, the rate appears to be lower in the subgroup of patients with baseline resistance-associated substitutions in nonstructural protein 5A.
Combination therapy with the NS5A inhibitor ledipasvir and NS5B inhibitor sofosbuvir appears to be highly effective in the management of chronic hepatitis C virus genotype 1 infection, yielding a sustained virologic response of >90 percent without increasing the incidence of serious adverse events, according to data from a real-world Japanese cohort.
Hepatitis C virus (HCV) treatment may benefit patients with HCV-related hepatocellular carcinoma (HCC) who respond to the initial HCC palliative treatment, suggest the results of a study, adding, however, that treating HCV in HCC patient undergoing noncurative HCC treatment remains debatable.
The combination of sofosbuvir with either simeprevir or daclatasvir is safe and very effective for the treatment of hepatitis C virus (HCV)-genotype 4 (GT4) infection, reports a new study. In addition, treatment response is not affected by cirrhosis and failure of prior interferon-based therapy.
Use of adalimumab or infliximab in biologic-naïve patients with inflammatory bowel disease (IBD) delivers comparable rates of corticosteroid-free remission, as shown by a study presented at the Advances in Inflammatory Bowel Disease (AIBD) Conference 2019.